US Pharma MarketingBraveheart lands $383M IPO to take Hengrui cardio drug into Phase 3
For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq. Braveheart Bio priced its
For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq.
Braveheart Bio priced its
Source: Endpoints News